Clinicopia Labeling On-Demand from InfoPro Solutions, Inc. Revolutionizes Clinical Labeling: Reducing Overall Costs and Increasing Quality Control
For the first time, midsize pharmaceutical and biotechnology companies engaged in clinical trials can cost effectively create, approve and print their labels in-house using InfoPro's Clinicopia Labeling On-Demand.
WESTLAKE VILLAGE, Calif., May 26, 2005 -- InfoPro Solutions, Inc. (www.infoprosolutions.com ) today announced Clinicopia Labeling On-Demand, a new hosted service accessed securely via the internet that delivers the full functionality and benefits of a clinical labeling system, without the time and costs associated with validating and deploying a new application in-house. Clinicopia Labeling on Demand revolutionizes clinical labeling by giving users in-house labeling functionality without an upfront investment.
"Clinicopia Labeling On-Demand is an essential tool for midsize pharmaceutical and biotechnology companies that may otherwise be burdened with print run minimums or large upfront investments," said Douglas Meyer, Senior Vice President, Pharmaceutical Science, at InfoPro Solutions. "With this solution these companies can bring their label development and printing in-house in the most economical way possible."
Clinicopia Labeling On-Demand provides the complete functionality needed to develop labels to be used on packages associated with clinical trials. Providing access via the internet, the solution gives users the ability to create, approve/reject and print labels all in a fully traceable process. Randomization numbers and other variable data can be integrated prior to final printing.
Compared to a "traditional" labeling system, Clinicopia Labeling on Demand lowers a company's start up and maintenance costs considerably. The end user is no longer responsible for many of the operational costs. The usage-based fee includes the use of the software, the associated support services, the use of the hardware and communications infrastructure, and all systems administration costs.
About InfoPro Solutions
Since 1995, InfoPro Solutions has been developing, implementing and maintaining enterprise-class, mission-critical information systems for the drug development markets within the pharmaceutical and biotechnology industries. InfoPro Solutions has developed numerous solutions in the clinical trials space to help their customers manage their extended supply chains. Clinicopia Suite is the world's first purpose built, industry specific Clinical Trials Supply Management Suite developed from the ground up. The On Demand services offer the full functionality and benefits of the Clinicopia Suite as a hosted service. InfoPro Solutions' list of customers includes AstraZeneca, Abbott Laboratories, Procter & Gamble, Chiron and Pfizer. InfoPro has offices in Los Angeles, Boston, Frankfurt and an offshore development center in Bangalore.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
